In 2022, Guo et al. found that under hypoxic conditions, the androgen receptor regulated the stem cell phenotype of RCC through the lncTCFL5-2/YBX1/SOX2 signaling axis, thereby enhancing RCC cell resistance to sunitinib[75]. The gene discussed is AR; the disease is renal cell adenocarcinoma.